Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | UBE2M | P61081 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072821 | 0.89 | EPHX2 (0.75) | CXCR3CA12CA1CA2CA9 | |
| SCHEMBL2718126 | 0.89 | EPHX2 (0.73) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL1443815 | 0.84 | KDM4E (0.54) | CXCR3STS | |
| SCHEMBL1444668 | 0.82 | CXCR3 (0.62) | CXCR3EPHX2MEN1UBE2MKMT2A | |
| SCHEMBL6863335 | 0.82 | STS (0.56) | CXCR3EPHX2STS | |
| SCHEMBL2955532 | 0.81 | CA12 (0.70) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL2732584 | 0.81 | CA12 (0.63) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL14997508 | 0.80 | CA12 (0.71) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL5001323 | 0.80 | EPHX2 (0.68) | CA12CA1CA2CA9EPHX2 | |
| SCHEMBL14997957 | 0.80 | EPHX2 (0.76) | CA12CA1CA2CA9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | CXCR3 2678/4885CA12 2320/4885CA1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.